samedan logo
 
 
spacer
home > epc > autumn 2006 > taming the ectd
PUBLICATIONS
European Pharmaceutical Contractor

Taming the eCTD

Dr Gareth Williams of Octagon Research Solutions whets the appetite of every pharma company when he suggests that finding a sure-fire way to increase your chances of meeting regulations consistently and hitting deadlines on time is more than just a pipe dream

Consider the large, global conglomerate with research, development, manufacturing and supply organisations spread across multiple continents. Hundreds of authors are engaged in the preparation of thousands of documents spread over several years – all converging in a series of late stage tasks that occur in the final month or two prior to submission. Assembly of the final submission – traditionally the realm of regulatory operations professionals – has received much attention over recent years, with all manner of tools emerging to automate the formatting, publishing, hyperlinking and collation of the final ‘product’. The fact remains, however, that much of this lastminute effort amounts to unnecessary revision, fixing up things that could have been ‘done right the first time’ earlier on in the submission’s life cycle. Given the consequences of failing to comply with agency regulations, and the financial implications of missing submission deadlines, these traditional ‘panics’ are unlikely to be tolerated for much longer.

Regulatory requirements are changing rapidly, especially with the inexorable drive towards electronic submissions, and the introduction of the electronic Common Technical Document (eCTD). eCTD is having a major impact on companies large and small, since it inherently requires that submission documents are broken down into smaller components, prepared by multiple authors. This higher granularity, coupled with the need to provide extensive hyperlinking and cross-referencing for ease of navigation and review, has added significant process complexity.

Everyone from global multinationals to smaller biotechs has been forced to take a close look at their authoring and review processes. The smarter companies are realising the benefits of creating documents ‘with the end in mind’: empowering authors to create submission-ready documents right up-front, instead of relying on regulatory operations to mould them into shape later. Enter the world of document standards.

WHAT EXACTLY DO WE MEAN BY DOCUMENT STANDARDS?

Document standards consist of an author’s toolkit to facilitate efficient preparation of consistent, submission-ready documents across the organisation. Though the tools in that kit may vary according to specific needs, best practice encourages the inclusion of the following.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Gareth Williams has over 20 years’ consulting experience, primarily in knowledge management, groupware and business process improvement. He currently works in the Process Solutions group at Octagon Research Solutions, a process-centric solutions provider offering regulatory, clinical, process and IT solutions to the life sciences industry. Prior to joining Octagon, Gareth held several internal and external consulting roles, working in all phases of the drug development life cycle from discovery through to postmarketing. His pharmaceutical clients have included Astra Hässle, Wellcome, Procter & Gamble, Abbott Laboratories, Novo Nordisk, SmithKline Beecham, British Biotech and Johnson & Johnson. Gareth holds a BSc (Hons) in Applied Chemistry and a PhD in Chemistry, both from Portsmouth University in England.
spacer
Dr Gareth Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

New PFA SonicLine® ultrasonic flowmeters

Flow measurement with ultrasound fast, precise, free from contamination         The new PFA SonicLine® ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLine® is also ideally suited for accurate batch and dosing processes with high reproducibility.              
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement